RecruitingPhase 1NCT07198555

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis .


Sponsor

Belief BioMed (Beijing) Co., Ltd

Enrollment

81 participants

Start Date

Oct 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-A101 to treat participants with knee osteoarthritis.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BBM-A101, a drug called BBM-A101, and others for people with knee osteoarthritis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 40 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBBM-A101

Single-dose intra-articular (IA)injection (2ml)(phase Ia) Low dose group, Middle dose group; High dose group; Control group :Placebo

DRUGPlacebo

Placebo(phase Ia)

DRUGBBM-A101

Single-dose intra-articular (IA)injection (2ml)(phase Ib) Low dose group, High dose group Control group :Placebo

DRUGPlacebo

Placebo(phase Ib)


Locations(2)

Shenzhen Second People's Hospital

Shenzhen, Guangdong, China

The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07198555


Related Trials